NRC Health Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. NRC Health provides subscription-based solutions for healthcare organizations to measure patient experience, service recovery, and employee engagement. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $34.8 million | $33.6 million |
| Net Income | $3.2 million | $5.8 million |
| Operating Income | $5.6 million | $8.6 million |
| Operating Margin | 16% | 26% |
| Diluted EPS | $0.14 | $0.25 |
| Operating Cash Flow | $7.2 million | $6.6 million |
| Free Cash Flow | $5.3 million | $3.7 million |
| Total Debt (Notes Payable) | $78.4 million | $79.4 million |
| Cash and Equivalents | $2.5 million | $2.5 million |
| Total Recurring Contract Value (TRCV) | $152.1 million | $134.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 4% year-over-year, driven by $0.6 million in higher recurring revenue from existing customers and $0.5 million from new customers.
- Profitability Decline: Operating income decreased 35% to $5.6 million. This was primarily due to a 30% increase in Selling, General, and Administrative (SG&A) expenses, driven by $1.4 million in higher stock-based compensation and executive salary expenses related to leadership transitions.
- Expense Increases: Direct expenses rose 5% due to higher third-party software costs and IT contractor spending. Depreciation and amortization increased 41% following the completion of headquarters renovations in June 2025.
- TRCV Growth: Total Recurring Contract Value grew 13% to $152.1 million, indicating strong underlying contract retention and new sales despite the GAAP earnings decline.
Outlook, Risks, and Unusual Items
- Significant Subsequent Event (Q2 Impact): In April 2026, the Board approved amendments to executive equity awards. This is expected to result in approximately $9.4 million of expense in Q2 2026, consisting of $6.5 million in non-cash accelerated equity compensation and $2.9 million in cash bonuses. This will negatively impact the effective tax rate for the remainder of 2026 due to non-deductibility.
- Liquidity: The company reported a working capital deficit of $18.5 million, largely due to significant deferred revenue balances. However, management cites sufficient liquidity via $2.5 million in cash, $30.0 million in revolving credit availability, and $27.6 million in delayed draw term loan availability.
- Capital Allocation: The Board authorized a new $60.0 million stock repurchase program in March 2026. The company repurchased 109,701 shares for $1.9 million in Q1.
- Risks: Key risks include customer contract non-renewal, competitive pressure, potential cyber-attacks, and the impact of healthcare industry consolidation.
Investor Verification Checklist
- Q2 Expense Spike: Verify the impact of the $9.4 million one-time executive compensation expense on Q2 2026 earnings and cash flow.
- Working Capital Deficit: Review the composition of the $18.5 million working capital deficit to ensure it is driven by deferred revenue (a non-cash liability) rather than operational cash burn.
- Debt Covenants: Confirm continued compliance with the Credit Agreement's fixed charge coverage ratio (1.10x) and cash flow leverage ratio (3.50x) given the upcoming Q2 expense hit.
- TRCV vs. Revenue Lag: Monitor the conversion of the 13% TRCV growth into GAAP revenue in subsequent quarters, noting the typical lag between contract signing and revenue recognition.